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ABSTRACT 
Exudative age related macular degeneration (AMD) is related to active choroidal neovascularization (CNV) and formation 
of disciform scars. Vascular endothelial growth factor (VEGF) mediated choroidal vascular endothelial cell (CVECs) 
proliferation is characteristic of CNV. Intravitreal injections of bevacizumab, ranibizumab and aflibercept (anti-VEGF 
monoclonal antibodies) are used to treat exudative AMD. Pazopanib, a tyrosine kinase inhibitor, inhibits 
neovascularization through blockade of intracellular tyrosine kinase VEGF receptor and platelet-derived growth factor 
receptor. In this in vitro investigation, we evaluated the inhibitory consequences of escalating doses of pazopanib on 
proliferation of VEGF-enriched CVECs to establish a safe dosage range. VEGF (50 ng/mL) enriched CVECs were treated 
with escalating doses of pazopanib (10, 50,100 and 250 µM). Cell proliferation rates (WST-1 assay), cell viability (trypan 
blue exclusion assay), and reactive oxygen species (ROS) levels were measured at 48 hours (h), 72h and 1 week. 
Intracellular caspase 3 levels and morphological changes were recorded. VEGF enriched CVECs showed a significant 
decrease in cell proliferation rates after one week of treatment with increasing doses of pazopanib (10, 50,100 and 250 
µM) treatment i.e. 87.8%, 43.0%, 38.1% and 9.3% compared to controls (p<0.001). Similarly, trypan blue exclusion assay 
revealed a decrease in cell viability as 81.8%, 81.0%, 53.4% and 8.7%, respectively (p<0.05). Further, pazopanib actively 
inhibited proliferation of VEGF-enriched CVECs, with 1.32, 1.92, 1.92 and 4.1-fold increase (p<0.01) in intracellular 
caspase 3 levels. VEGF-enriched CVECs treated with escalating doses of pazopanib decreased cell viability and increased 
caspase 3 levels in a time and dose dependent manner. 
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INTRODUCTION
Age-related macular degeneration (AMD) is the most 
common retinal cause of visual impairment in the United 
States at present
 
[1]. Neovascular (exudative) AMD, is a 
less common condition but with more advanced and 
aggressive form of AMD, which affects 15% of cases and 
involves active choroidal neovascularization (CNV) and 
formation of disciform scar at late stages
 
[2]. 
Pathophysiology of CNV is characterized by vascular 
endothelial growth factor (VEGF) mediated choroidal 
vascular endothelial cell (CVECs) proliferation, a potential 
target for antivascular endothelial growth factor therapy 
(anti-VEGF) [3].In the past, CNV associated with AMD was 
treated by transferring thermal energy to the 
proliferating CVECs with conventional or modified laser 
(photodynamic therapy) [4]. Nevertheless, thermal 
energy lacked the differential tissue sensitivity and 
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destroyed the proliferating CVECs together with the 
overlying retina. Loss of stable CVECs may lead to further 
ischemia, consecutive upregulation of VEGF and 
consequences in recurrent proliferation of abnormal 
CVECs [5]. 
The imbalance between proangiogenic and 
antiangiogenic factors has been associated with a 
number of severe eye diseases such as neovascular AMD, 
diabetic retinopathy, sickle cell retinopathy and 
retinopathy of prematurity [6-9]. Although 
neovascularization is a complex process involving 
endothelial cell proliferation, migration and tissue 
degradation, VEGF inhibition is sufficient to inhibit CNV. 
Accordingly, VEGF inhibitors has been used to control 
neovascularization in pathological conditions such as 
cancer [10], retinopathy of prematurity [11] and 
neovascular AMD [12]. 
Bevacizumab intravitreal injection as an anti-VEGF 
monoclonal antibody is effective in the treatment of 
exudative AMD. Ranibizumab and Aflibercept are other 
anti-VEGF drugs used in the treatment of various ocular 
diseases [13].
 
Newer and experimental medications such 
as Brolucizumab and Abicipar (single-chain antibody 
fragment) are currently in Phase 3 trials and may 
complement the treatment of neovascular AMD [14-18].
 
Pazopanib, a tyrosine kinase inhibitor (TKI), (FDA 
approved drug for advanced or metastatic renal cell 
carcinoma), inhibits neovascularization through blockade 
of intra-cellular tyrosine kinase VEGF receptor and 
platelet-derived growth factor receptor (PDGFR) [19]. 
This makes pazopanib an attractive and compelling 
alternative for consideration in the treatment of 
neovascular AMD. Preliminary clinical studies 
establishing the efficacy of pazopanib in the 
management of CNV is encouraging [19]. However, the 
dose and mechanism of action of pazopanib is empiric. 
In this in vitro study, we studied the inhibitory effects of 
escalating doses of pazopanib on the VEGF-enriched 
CVECs proliferation to establish a safe dose range. 
METHODS 
Cell culture 
Ethical approval for this study was received from our 
academic institution. Choroidal vascular endothelial cells 
(CVECs) (RF/6A) were taken from the American Type 
Culture Collection (ATCC-Manassas, VA. # CRL-1780) and 
cultured in Eagle’s minimal essential medium (EMEM; 
Invitrogen, Carlsbad, CA, The USA) comprising 10% fetal 
bovine serum (FBS; Sigma, St. Louis, MO, The USA), 100 
units/mL penicillin, and 100 microgram per millilitre 
(μg/mL) streptomycin. These choroidal cells were 
retained in log phase growth. Cells were harvested at    
37 °C in logarithmic scale in 75 Square Centimeter cell 
culture flasks. 
Enrichment of choroidal vascular endothelial cells with 
VEGF 
CVECs were treated with 50 nanogram/milliliter (ng/mL) 
doses of human VEGF165 (Pepro Tech, Rocky Hill, NJ, The 
USA) to keep cells in stable optimal proliferative mitotic 
stage and imitate human disease processes (sub-retinal 
neovascular membrane [SRNVM]) and proliferative 
diabetic retinopathy (PDR). Successive experiments were 
conducted employing CVECs enriched for 48 hours using 
VEGF (50 ng/mL) [6]. 
Treatment of CVECs with Pazopanib 
CVECs were treated with increasing doses of pazopanib 
(Santa Cruz, The USA) at concentrations of 10, 50, 100 
and 250 µM. The exposure was maintained up to a 
maximum period of one week and cellular activity was 
re-evaluated at different time points (48h, 72h and 1 
week) for all pazopanib concentrations. Cell viability was 
compared to control cells not treated with pazopanib. 
Tested and control cells were surveyed at the same time 
points. 
Assessment of Cellular Viability 
Cell proliferation using WST-1 Assay 
VEGF enriched CVECs were plated at a density of 20,000 
cells/well in 96 well plates for 48h and then exposed to 
different concentrations of pazopanib as 
aforementioned. Cellular growth was re-evaluated in 
accordance with the manufacturer’s guidelines with the 
4-[3-(4-lodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-
1.3-benzene disulfonate (WST-1) kit (Roche, Mannheim, 
Germany). The colorimetric assay in viable cells depends 
on the mitochondrial dehydrogenases induced cleavage 
of the tetrazolium salt WST-1. WST-1 solution (100 
µl/well) was added to cells in 6-well plates and 
subsequently incubated for one hour at 37 °C. The plate 
was recorded on a spectrophotometer at wavelength 
440 nanometer (nm) with a reference at 690 nm. 
Trypan blue exclusion assay 
Trypan blue staining in conjunction with an automated 
cell viability analyzer was used (Vi CELL XR (Beckman 
Coulter, Inc., Brea, California, The USA) to evaluate 
cytotoxicity. VEGF enriched CVECs were plated at a 
density of 20,000 cells/well in 6-well plates, treated with 
escalating doses of pazopanib. At standardized interval, 
cells were trypsinized with 1 mL of Trypsin-EDTA 
(Invitrogen) for 3 min at 37ºC. In line with the 
manufacturer’s instructions, cells were resuspended in 
500 µL growth media and tallied immediately using the 
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ViCell XR Cell Proliferation Analyzer (Beckman-Coulter, 
Brea California, The USA). We documented automated 
cell proliferation tallies together with total number of 
cells. 
Measurement of Reactive oxygen species (ROS) 
Intracellular ROS was measured using 
dihydrorhodamine123 (AnaSpec EGT, Fremont, California, 
The USA), as a freely permeable non-fluorescent probe that 
identifies mitochondria, and fluoresces after oxidation by 
ROS. Cells were treated with 10 µM Dihydrorhodamine123. 
On excitation at 485 nm, rhodamine fluoresces at 528 nm, 
which was assessed applying multidetection microplate 
reader at separate time intervals. 
Intracellular analysis of caspase assay 3 activity 
The levels of activated caspase 3 were investigated at 
72h, (a protease instrumental in the induction of 
apoptosis) after treatment with different doses of 
pazopanib. Activation of caspase 3 was recorded 
according to the manufacturer’s instructions (Thermo 
Scientific, Logan, UT, The USA). Briefly, following 
treatment of cells with variable doses of pazopanib, 
cells were fixed with 4% paraformaldehyde and 
permeabilized for 15 minutes using 31 surfactants X-
100. Cell permeabilization was quenched with 30% 
hydrogen peroxide after that a blocking buffer was 
added for 30 minutes. Thereupon, cells were 
incubated with 1:500 dilution of anti–caspase 3 and a-
tubulin (control), at 48 °C overnight. Then washed and 
were incubated for 30 minutes at ambient 
temperature with the anti-rabbit HRP conjugate. 
Afterwards, 3,3’,5,5’ Tetramethylbenzidine substrate 
was added. Cleaved caspase-3 protein levels were 
analyzed by grading the absorbance at 450 nm with 
microplate reader. We correlated the outcomes 
against a-tubulin control following detection with 
background absorbance and defined  as percentage. 
Experiments were repeated three times to ensure 
repeatability of results.  
Cellular morphology 
To observe the morphological changes, control cells, 
along with cells exposed to different doses of pazopanib 
were plated in 6 well plates. Each well was assessed 
independently under a microscope named as bright-field 
phase contrast IX51 (Olympus, Center Valley, 
Pennsylvania, The USA) at different time intervals. Cell 
architecture and morphology were re-examined after the 
cells were exposed to increasing doses of pazopanib. 
Signs of gross cellular injury e.g. variations in cytoplasmic 
or nuclear appearance as a result of cytotoxicity, were 
analyzed in both treated and control cells. For each dose 
studied, randomly selected photographs were taken at 
20X magnification and evaluated. 
Statistical analysis 
Each experiment was repeated three times for each cell 
type at each pazopanib dose and time points. The mean 
± standard deviation (SD) was reported. Statistical 
analysis was performed using ANOVA (Graphpad Prism, 
La Jolla Ca, The USA). P value<0.05 was considered as 
statistically significant. 
RESULTS 
VEGF enriched CVECs Cell Proliferation: WST-1 Assay 
The proliferation of CVECs in response to different 
concentrations of pazopanib at various time points is 
summarized in Table 1 and Figure 1. The growth rates 
were evaluated with WST-1 assay and described as 
percentage of surviving cells. 
 
 
Table 1: Proliferation of CVECs in response to different concentrations of pazopanib at various time points. The proliferation rates 
were assessed using WST-1 assay. 
Cell type / Incubation Time Pazopanib Concentration (μM) 
CVECs 10 50 100 250 
48h; mean ± SD 91.8%±4.74 83.1%±6.3 77.5%±1.87 8.2%±8.05 
72h; mean ± SD 65.1%±19.8 88.2%±6.9 61.8%±13.4 9.3%±9.1 
1Week; mean ± SD 87.8%±15.3 43.0%±6.7 38.1%±18.3 9.3%±24.9 
Abbreviations: μM: micromolar; CVECs: choroidal vascular endothelial cells; h: hours; SD: standard deviation. 
 
48-hour Time point 
Treatment of VEGF enriched CVECs treated with various 
concentrations of pazopanib induced a decreased in 
cells-variability by 91.8% (p<0.001), 83.1% (p<0.001), 
77.5% (p<0.001) and 8.2% (p<0.001) for pazopanib 
concentrations of 10, 50,100 and 250 µM, respectively 
compared to control cells (Table 1 and Figure 1). 
72-hour Time Point 
Treatment of VEGF enriched CVECs with pazopanib 
(10, 50,100 and 250 µM) concentrations resulted in a 
decrease in cell proliferation rates as 65.1% 
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(p<0.001), 88.2% (p<0.001), 61.8% (p<0.001) and 
9.3% (p<0.001) compared to control cells (Table 1 and 
Figure 1). 
One-week time point 
Based on WST-1 assay cell proliferation assay, at one-
week time point, VEGF enriched CVECs also showed a 
decrease in cells proliferation rate at 87.8% (p<0.001), 
43% (p<0.001), 38.1% (p<0.001) and 9.3% (p<0.001) 






VEGF enriched CVECs Cell Proliferation: Trypan blue 
exclusion assay  
The percentage of viable cells of VEGF enriched CVECs in 
response to pazopanib treatment at different 
concentrations and various time points is summarized in 
Table 2. The cells viability rates were assessed with 
trypan blue exclusion assay as described in methods and 
presented as percentage of surviving cells (Figure 2). 
48-hour Time point 
Treatment of VEGF-enriched CVECs with pazopanib (10, 
50,100 and 250 µM) showed decrease in viability by 
56.9% (p=0.001), 39% (p=0.0001), 13.7% (p<0.0001) and 
12.2% (p<0.0001) compared to controls (Table 2 and 
Figure 2). 
 
Table 2: The percentage of viable cells of VEGF enriched CVECs in response to pazopanib treatment at different concentrations and various time points. The cells 
viability rates were assessed using trypan blue exclusion assay as described in methods. 
Cell type / Incubation Time Pazopanib Concentration (μM) 
CVECs 10 50 100 250 
48h; mean ± SD 56.9%±29.5 39.0%±4.31 13.7%±15.1 12.2%±13.7 
72h; mean ± SD 65.8%±11.3 50.61%±40.7 44.8%±14.4 3.8%±4.4 
1Week; mean ± SD 81.8%±16.2 81.0%±16 53.4%±13.9 8.7%±6.1 
Abbreviations: μM: micromolar; VEGF: vascular endothelial growth factor; CVECs: choroidal vascular endothelial cells; h: hours; SD: standard deviation. 
72-hour Time Point 
At 72-hour time point, VEGF-enriched CVECs showed a 
decline in cell viability after treatment with pazopanib by 
65.8% (p=0.001), 50.61% (p<0.001), 44.8% (p<0.001) and 
3.8% (p<0.001) as compared to control cells (Table 2 and 
Figure 2). 
One-week time point 
Based on trypan blue exclusion cell viability assay, at 
one-week time point, treatment of VEGF-enriched 
CVECs with pazopanib showed similar trend i.e. 
decrease in cell viability by 81.8% (p=0.24), 81% 
(p=0.21), 53.4% (p=0.001) and 8.7% (p<0.0001) as 
compared to control cells (Table 2 and Figure 2). 
Intracellular reactive oxygen species levels after 
pazopanib treatment 
Figure 3 summarizes the changes in the levels of ROS as a 
result of treatment of pazopanib at different 
concentrations and at different time intervals. At 48h, 
treatment of VEGF-enriched CVECs with pazopanib (10, 
50,100 and 250 µM) resulted in 0.94%, 0.94%, 1% and 8 
% increase in the ROS levels compared to controls. 
Similarly, at 72h ROS levels were increased by 4%, 2%, 8% 
and 6% compared to controls. Furthermore, at 1 week, 
ROS levels were increased by 10%, 4%, 12% and 15 % 
compared to controls. The results indicated a trend of 
increased levels of ROS by increasing pazopanib 
concentration. However, the increased difference 
between exposed cells and the control cells were not 
statistically significant. 
Activated Caspase 3 Evaluation: 
Treatment of VEGF enriched CVECs with varying doses of 
pazopanib (10, 50,100 and 250 µM) resulted in a dose 
dependent increase in the release of caspase-3 from 
cells. At 72h, 1.38, 1.92, 1.92 and 4.1 fold increase 
(p<0.001) in the caspase-3 levels were observed 
compared to controls (Figure 4). These results suggest 
that pazopanib actively inhibits the proliferation of VEGF 
enriched CVECs through promotion of apoptosis. 
Morphology of VEGF enriched CVECs 
Cellular changes after pazopanib treatments (10, 50,100 
and 250 µM) were assessed by bright field microscopy 
(Olympus Corporation, Tokyo, Japan) at 48h. 
Representative photographs are presented in Figure 5. 
Bright field microscopy of VEGF enriched CVECs in 
culture, revealed a decrease in cell size and irregular 
membrane structure after exposure to high pazopanib 
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Figure 1: Effect of pazopanib (10, 50, 100, and 250 µM) on choroidal vascular endothelial cells (CVECs) enriched with vascular endothelial growth factor (VEGF: 
50ng/mL). Cell proliferation was determined by WST-1 assay at different time intervals. Results expressed as percentage of cell proliferation compared to control. 





Figure 2: Effect of pazopanib (10, 50, 100, 250 µM) on choroidal vascular endothelial cells (CVECs) enriched with vascular endothelial growth factor (VEGF: 50ng/mL). Cell 
viability was defined by trypan blue assay using ViCell XR Cell analyzer at different time intervals. Results expressed as percentage of cell proliferation compared to control. 
A. 48h, B. 72h, and, C. 1 Week. Abbreviations: µM: micromole; ng/mL: nanogram per millilitre; h: hour; %: percentage; Conc.: concentration. 
 
   
 
 
Figure 3: Reactive oxygen species (ROS) levels measured using dihydrorhodamine 123 (DHR 123) after exposure to various concentrations of pazopanib at 
different time intervals. A. 48h, B. 72h, and, C. 1 Week.  
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Figure 4: Measurement of activated caspase-3 levels in CVECs enriched 
with VEGF treated with different concentrations of pazopanib at 72h 
showed a 5-fold increase in activated caspase 3 levels compared to 
control. Abbreviations: µM: micromole; h: hour; VEGF: vascular 
endothelial growth factor; CVECs: choroidal vascular endothelial cells; 
Conc.: concentration. 
Discussion 
Our study confirmed that VEGF-enriched CVECs treated 
with escalating doses of pazopanib decreased cell 
viability and increased caspase 3 levels in a time and 
dose dependent manner. Since, AMD is the foremost 
etiology of blindness in the elderly in developed 
countries, we believe that our findings supplement the 
ongoing efforts in development of new pharmacologic 
and therapeutic measures. 
Often vision loss caused by AMD is attributed to 
neovascular form of the disease [1]. Anti-angiogenic 
drugs that target VEGF are very effective in treating 
exudative AMD and currently used as a standard of care 
in management of active AMD. However, they need 
multiple intravitreal injections, usually monthly. 
Hypothetically, the immature proliferating CVECs are a 
target for anti-angiogenic agents to inhibit proliferation. 
Although few clinical investigations evaluated the 
therapeutic action of pazopanib in the treatment of CNV, 
there is no preclinical data that examined the dose of 
pazopanib necessary for inhibition of the CVEC 
proliferation [19]. In addition, poor therapeutic response 
was observed at the doses tested in the clinical trial [19].  
In this study, we investigated and found a dose-
dependent inhibition of proliferating CVECs after 
exposure to Pazopanib, a multi-targeted tyrosine kinase 
inhibitor of VEGF receptors (VEGFRs)-1, VEGFRs-2 and 
VEGFRs-3, stem cell growth factor C-Kit-17 and PDGFRs-α 
and β. This small molecule is a potent antiangiogenic 
molecule and FDA approved biological agent used in the 
treatment of soft tissue sarcoma and advanced renal cell 
carcinoma.  
Pazopanib in eye drop (5mg/mL) and oral formulations 
has been investigated for medical treatment of 
neovascular AMD [19-22]. However, topical eye drops 
were clinically ineffective. Pazopanib may inhibit the 
similar pathway clinically substantiated and confirmed in 
AMD with anti-VEGF therapies, but through inhibition of 
tyrosine kinase receptor. Added benefit may derive from 
inhibition of the pro-angiogenic PDGF pathway. PDGF 
stabilizes new vessels and basement membrane and 
enhances resistance to anti-VEFG agents. Inhibition of 
PDGFR-α and PDGFR-β, in conjunction to inhibition of the 
VEGF pathway, could lead to lasting CNV regression. To 
the best of our knowledge this is the first report 
establishing the inhibitory effects of escalating doses of 
pazopanib on proliferation of VEGF-enriched CVECs. 
Pazopanib, a multi-targeted tyrosine kinase inhibitor of 
VEGF receptors promotes cell damage and death. In the 
current study, reduction in cell viability positively 
correlated with an increase in dose at different time 
intervals. This suggests that pazopanib induces vascular 
cell death through the blockage of tyrosine kinase (that 
was sustained days) following treatment. 
Sequential increase in cell death with increasing 
concentration of pazopanib was observed with WST-1 
assay. There was variable response in cell viability with 
10 and 50 µM concentrations of pazopanib. There was a 
linear decrease in cell viability with increase in time 
(p<0.001) at 100 µM concentration. At 250 µM 
concentration, toxic effect of pazopanib was noted, with 
death of 91% of cells (both at 48 hours and 1 week time 
points). Contrary to the results of WST-1, the results of 
trypan blue exclusion assay showed an increase in cell 
viability over the course of time at 10, 50 and 100 µM 
concentrations. Maximum cell death was noted after 48 
hours of exposure. However, the number of dead cells 
decreased at 72 hours or 1 week. 
 
 
Figure 5: Effects of various concentrations of pazopanib on cell morphology of VEGF enriched choroidal vascular endothelial cells at 250 micromole (µM). A 
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At 250 µM concentration, the toxic effect of pazopanib 
was noted at all the time points. Similar to WST-1, there 
was an increase in cell death with increased 
concentration of pazopanib. This difference in response 
between the results of the two methods is probably 
secondary to dissimilar underlying mechanisms. The 
property of trypan blue exclusion assay is staining of 
dead cells and injured cell membrane while the basis of 
WST-1 assay is the enzymatic cleavage of the tetrazolium 
salt WST-1 by cellular mitochondrial dehydrogenases 
available in viable cells. WST-1 produces a mass response 
(quantitative data), whereas trypan blue method 
provides a response from the individual cell (qualitative 
data). While the trypan blue exclusion assay may have 
higher specificity for cell death detection, the WST-1 
assay has a higher sensitivity. 
Morphologic changes showed a decrease in cells size and 
irregular membrane structure and this was more evident 
at high pazopanib concentration of 250 µM (toxic effect 
of pazopanib at higher concentration). ROS generated 
from the interaction of cell membrane lipids, are known 
as cell damage and death inducer. There was an increase 
in ROS compared to the controls with exposure to 
pazopanib, though not statistically significant. Similarly, 
there was a gradual increase in the levels of caspase-3 on 
treatment with varying doses of Pazopanib and an 
exponential increase was observed at 250 µM 
concentration compared to controls, suggesting that 
pazopanib actively inhibits the proliferation of VEGF 
enriched CVECs and further promotes apoptosis. 
Danis et al. reported the applicability of eye drop 
formulation of pazopanib in patients with CNV. They 
noted significant improvement in mean vision at 1 month 
[19]. However, improvement in macular edema was 
found only in the subset of subjects [CFH Y402H TT 
genotype]. Csaky et al. In a study on patients with AMD 
who had previously received intravitreal injections 
evaluated the effect of daily pazopanib eye drops 
(5mg/mL QID) on the stability or improvement of visual 
acuity, along with a decrease in the continuous need for 
intravitreal injections [23]. They also evaluated the 
safety, tolerability and changes in the retina associated 
with this eye drop and determined the steady-state 
plasma concentration of the drug after administration of 
the eye drop. They concluded that the eye pazopanib eye 
drops did not reduce the frequency of as-needed 
injections. Pazopanib eye drop did not show increased 
efficacy in this study because of insufficient transduction 
of active drug to the relevant ocular tissues 
(retina/choroid). However, the drop, administered four 
times daily for 52 weeks, was well tolerated by patients. 
Its ophthalmic and non-ocular complications were also 
mild and no drug-related severe adverse effects were 
reported.  
Takahashi et al. reported regression of CNV in mouse 
model after oral administration of pazopanib [24]. 
Systemically administered drugs have their own 
disadvantages. Usually lower amount of drug reaches the 
target tissue, large portion of the drug is destroyed 
metabolically before it reaches target tissue and there 
are unavoidable systemic side effects. Intravitreal 
injection of pazopanib is more likely to be effective 
therapeutically, as it provides necessary dose directly to 
the target tissue. Before the use of intravitreal 
pazopanib, its toxicity profile on choroidal and RPE cells 
needs to be evaluated. 
The main strengths of our current study include the 
reproducibility of the CVEC model, and reliability of the 
data through multiple methods including WST 1 assay, 
trypan blue assay, ROS levels and caspase essay 
performed in triplicates. The main limitation of the study 
was its in vitro nature. We believe that replication of 
these results through an animal model would validate 
the conclusions of our study and establish a dose that is 
required for inhibition of neovascular membrane with 
intravitreal injection of pazopanib. 
CONCLUSION 
In conclusion, our study showed that VEGF enriched 
proliferative CVECs are particularly sensitive to 
Pazopanib in a dose dependent manner and cell death 
results from inhibition of tyrosine kinase. Topical drops 
could be formulated with an intent to increase 
intravitreal concentration of Pazopanib in the range of 
250µM for therapeutic effect. 
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